Primary Site >> Colorectal Cancer

Gene >> TAB2

Journal: Bioconjug Chem. 2006 Mar-Apr;17(2):410-8.
Title: Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).
Author: Alderson, Ralph F|Toki, Brian E|Roberge, Martin|Geng, Wei|Basler, Joshua|Chin, Regina|Liu, Amy|Ueda, Roanna|Hodges, Douglas|Escandon, Enrique|Chen, Tianling|Kanavarioti, Tessi|Babe, Lilia|Senter, Peter D|Fox, Judith A|Schellenberger, Volker
PMID: 16536473
Journal: Curr Cancer Drug Targets. 2011 Oct;11(8):976-86.
Title: RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.
Author: Martin, S E|Wu, Z-H|Gehlhaus, K|Jones, T L|Zhang, Y-W|Guha, R|Miyamoto, S|Pommier, Y|Caplen, N J
PMID: 21834757
Journal: Biomed Res Int. 2013;2013:159786.
Title: Gemifloxacin, a fluoroquinolone antimicrobial drug, inhibits migration and invasion of human colon cancer cells.
Author: Kan, Jung-Yu|Hsu, Ya-Ling|Chen, Yen-Hsu|Chen, Tun-Chieh|Wang, Jaw-Yuan|Kuo, Po-Lin
PMID: 24386633